Len Getz
Primary Care · Memphis, TNNPI 1831172444
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,150 of the $25,228 with a category attached, or 71.9%. AbbVie accounts for 90.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $22,542 and has fallen 95.6% since, to $984 in 2025. Among primary care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $106.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- Takeda Pharmaceuticals U.S.A., Inc.$460
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$235
- Alkermes, Inc.$235
- Kowa Pharmaceuticals America, Inc.$212
- AstraZeneca$178
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$18,15072%
- Travel & lodging$3,64214%
- Food & beverage$3,43614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 88 | $22,763 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $460 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $235 |
| Alkermes, Inc. | 7 | $235 |
| Kowa Pharmaceuticals America, Inc. | 14 | $212 |
| AstraZeneca | 3 | $178 |
| Vanda Pharmaceuticals Inc. | 6 | $175 |
| Corium, LLC | 13 | $158 |
| Lilly USA, LLC | 9 | $147 |
| Novo Nordisk | 9 | $130 |
| Boston Scientific | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Johnson & Johnson | 3 | $56 |
| Evoke Pharma, Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $41 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Merck | 1 | $16 |
| Pfizer | 1 | $16 |
| Biogen | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,228 in reported general payments places this provider in the 95th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $15,655 |
| JardianceEmpagliflozin | 20 | $15,289 |
| TrintellixVortioxetine Hydrobromide | 23 | $14,779 |
| OzempicSemaglutide | 13 | $12,094 |
| JanuviaSitagliptin Phosphate | 11 | $10,724 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 53 | $2,094 |
| Mirtazapine | 35 | $1,249 |
| ProgesteroneProgesterone, Micronized | 33 | $899 |
| Potassium Chloride | 19 | $808 |
| Levothyroxine Sodium | 41 | $532 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $514 |
| Aripiprazole | 18 | $436 |
| Estradiol | 19 | $418 |
| Rosuvastatin Calcium | 38 | $366 |
| Bupropion XlBupropion Hcl | 27 | $364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $22,763 | $15,65511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $460 | $14,77923 claims |
| Novo NordiskOzempic | $130 | $12,09413 claims |
| MerckJanuvia | $16 | $10,72411 claims |
| Lilly USA, LLCOlanzapine | $147 | $18211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 primary care providers in Tennessee.
Other primary care in Memphis
- Laura ReedMemphis$1K
- Mary SullivanGermantown$115K
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Reena BhaktaMurfreesboro$12K
- Ryan HartmanNashville$11K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
- Corey ClelandSevierville$9K
- Katie JohnsonClarksville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.